Imbruvica Gets Broad CLL Okay in EU But Draft Rebuff From UK's NICE
Executive Summary
AbbVie Inc. and Johnson & Johnson's Imbruvica (ibrutinib) has won a broader chronic lymphocytic leukemia (CLL) label in Europe but given a draft rebuff from NICE due to data ambiguity and told instead to file for inclusion in the UK's controversial government-funded Cancer Drugs Fund.